SCHEMBL7239776

SCHEMBL7239776

O=C(O)c1cc(Br)ccc1C(=O)Nc1nc(-c2ccc3ccccc3c2)cs1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.80
SORT1 Q99523 2/20 0.62
NPC1 O15118 2/20 0.60
CSNK2A1 P68400 3/20 0.59
CSNK2A2 P19784 1/20 0.59
CSNK2B P67870 1/20 0.59
CSNK2A3 Q8NEV1 1/20 0.59
GSTO1 P78417 1/20 0.56
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
RRM1 P23921 1/20 0.51
RRM2B Q7LG56 1/20 0.51
SIRT5 Q9NXA8 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
USP2 O75604 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7231423 0.96 RAB9A (0.80) RAB9ASORT1NPC1CSNK2A1CSNK2A2
SCHEMBL7239062 0.89 RAB9A (1.00) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B
SCHEMBL7239525 0.89 RAB9A (0.86) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B
SCHEMBL6153615 0.88 RAB9A (0.67) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B
SCHEMBL7240198 0.87 RAB9A (0.80) RAB9ASORT1NPC1CSNK2A1CSNK2A2
SCHEMBL7231284 0.84 RAB9A (0.74) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B
SCHEMBL7230092 0.83 RAB9A (0.80) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B
SCHEMBL7228332 0.83 RAB9A (0.80) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B
SCHEMBL1124116 0.83 RAB9A (0.79) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B
SCHEMBL7238318 0.81 RAB9A (0.80) RAB9ANPC1CSNK2A1CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-20 US disclosed
WO-2003006443-A2 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production TERT, POT1, REV1 RAB9A 3964/4885SORT1 2512/4885NPC1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.